Pharmaceutics, 2023 A significant number of deaths are reported annually worldwide due to microbial and viral infections. The development of protective medical textiles for patients and healthcare professionals has attracted many researchers’ attention.
Mohamed Hamdi +3 more
doaj +1 more source
Effects of 12-week treatment with Sovodak in patients infected by genotype 1 hepatitis C virus [PDF]
Journal of Research in Clinical Medicine, 2019 Introduction: It has been shown that the combination therapy of Sofosbuvir-Daclatasvir (Sof/Dac) has a high rate of success in the treatment of patients. For the first time, a single pill of Sof/Dac has been formulated in Iran (Sovodak).
Hosein Mehdipour +4 more
doaj +1 more source
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease [PDF]
, 2017 Background There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy.
Weis, Nina +18 more
core +4 more sources
Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]
Терапевтический архив, 2019 Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova +11 more
doaj +1 more source
Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors
Viruses, 2022 Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental ...
Tamer Nasr +7 more
doaj +1 more source
Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir. [PDF]
, 2017 Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus genotype 3, who suffered from an acute ...
Majoni, William, Ashraf, Taha
core +2 more sources
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh +14 more
doaj +1 more source
Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients [PDF]
International Journal of Medical Arts, 2021 Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV.
Mohamed G. Mohamed +3 more
doaj +1 more source
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 [PDF]
, 2020 OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2.
Mousaviasl, Sajedeh +21 more
core +1 more source
Pakistan Journal of Pharmaceutical Sciences, 2023 Cirrhosis and liver cancer are both caused by hepatitis C virus (HCV) infection of the liver. Patients with HCV cirrhosis may be treated with one of many antiviral medications, depending on their specific genotype.
Amin Ullah +14 more
doaj +1 more source